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Abstract 
Introduction: Failed cannulation in the right adrenal vein, which makes the sampling 
results in the contralateral vein and inferior vena cava (IVC) nonsense, is the main 
obstacle of using adrenal vein sampling (AVS) in the lateralisation diagnosis in primary 
aldosteronism (PA). We performed a retrospective study to evaluate the specificity and 
sensitivity of using the aldosterone index (AI) in PA lateralisation diagnosis. 
Material and methods: We enrolled 116 patients who were diagnosed with PA and 
then underwent AVS in the West China Hospital of Sichuan University from April 2015 
to April 2017. The AI, calculated by dividing the aldosterone concentration of the failed 
side by the aldosterone concentration of IVC, was used for lateralisation diagnosis if 
the cannulation was judged to be failed by traditional method. Patients with dominant 
adrenal gland based on successful AVS were included in subgroup 2 (n = 75), while the 
patients diagnosed with a dominant gland using AI method were enrolled in subgroup 
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1 (n = 41).  
Results: No significant difference of clinical and biochemical findings between the two 
groups was detected (p value after operation > 0.05). ROC analysis was performed to 
test the specificity and sensitivity based on the AI in subgroup 2. The AUC for dominant 
gland detection was 0.76, which resulted in 91.3% sensitivity and 67.53% specificity. 
The positive and negative likelihood ratios were 2.81. 
Conclusions: Our data suggested that the modified strategy using AI to diagnose the 
dominant gland in PA is an efficient method when cannulation has failed in the right 
side. 
Key words: primary aldosteronism; aldosterone-producing adenoma; adrenal vein 
sampling 
 
Introduction 
Primary aldosteronism (PA) is a major cause of secondary hypertension. 
According to epidemiological research, in about 5–15% of patients with hypertension 
it can be attributed to PA [1]. What is worse, about 65.6% of these patients suffer with 
secondary hypertension [2], and 15–20% have treatment-resistant hypertension [3]. 
Primary aldosteronism is also characterised by persistently high levels of plasma 
aldosterone and inhibited renin secretion [4]. It has been considered that patients with 
PA have higher morbidity and mortality from cardiovascular or cerebrovascular 
diseases, compared with patients with primary hypertension [5]. Thus, given the high 
incidence of PA and the corresponding serious cardiovascular diseases it elicits, it is 
becoming essential for proper diagnosis and treatment of PA. 
Specifically, on account of the variation in the management of different PA 
subtypes, screening PA and determining the dominant gland is of significant clinical 
value before medical treatment. For instance, aldosterone-producing adenomas (APA) 
should be treated with adrenalectomy, while pharmacological therapy is appropriate for 
bilateral adrenal hyperplasia [6]. According to guidelines from the Japan Endocrine 
Society 2009, plasma renin activity (PRA), plasma aldosterone concentration (PAC), 
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and PAC/PRA ratio (ARR) are used for screening PA in hypertensive patients [7]. For 
patients diagnosed with PA, it is recommended that abdominal computed tomography 
(CT) scan and AVS should be performed separately to verify the adrenal mass 
anatomically and functionally. AVS has been widely accepted as the “gold standard” 
for the subtyping of PA. However, AVS poses certain limitations in practical use due to 
its high failure rate in clinical practice, especially in conditions of failure in the right 
side [8–11]. Therefore, it is urgently needed to explore novel strategies to detect the 
dominant gland in PA patients.  
In this study, our group retrospectively analysed the clinical outcomes of 116 patients 
who followed the management routine of PA in the West China Hospital of Sichuan 
University. We compared the aldosterone concentrations measured in the adrenal vein 
and peripheral blood to determine the dominant gland in patients when sampling failed 
in the right side. Our developed strategy might provide a better alternative for 
lateralisation diagnostics in PA patients. 
 
Material and methods 
Study design and subjects  
In this retrospective analysis study, we followed up the clinical outcomes of patients 
who entered the clinical routine of PA management in the West China Hospital from 
April 2015 to April 2017. 133 patients diagnosed with PA in the endocrine department 
of West China hospital were sent for AVS and CT scan. Patients were enrolled in our 
study if they met the following criteria: 1 — AVS-detected dominant gland with 
ipsilateral adrenal lesion(s) and no adrenal lesion found in the contralateral gland; 2 — 
patients with bilateral adrenal lesions treated with unilateral adrenalectomy if there was 
a dominant gland; and 3 — if there was no adrenal lesion found by CT, adrenalectomy 
was performed when there was an AVS-detected dominant gland. Exclusion criteria 
included: 1 — drug addiction history (n = 1); 2 — contraindication for general 
anaesthesia (n = 2); and 3 — no dominant gland found by AVS (n = 14). Collectively, 
a total of 116 cases of patients with PA were enrolled in our study. Their clinical features 
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are listed in Table I. The experimental design, methods of clinical data collection, and 
strategies of data evaluation were performed in accordance with the approved 
guidelines. Written, informed consent was obtained from each participant. 
 
Management routine for primary aldosteronism  
Primary aldosteronism screening is recommended to patients who have drug-
resistant hypertension, unexplained spontaneous or diuretic-induced hypokalaemia, 
adrenal incidentaloma, sleep apnoea, a family history of early-onset hypertension, or a 
cerebrovascular accident at a young age (< 40 years). Patients with ARR values > 20 
(ng/dL)/(ng/mL·h) and PAC values > 15 ng/dL should undergo captopril challenge test. 
Patients with PAC > 12 ng/dL after administration of 50 mg captopril are diagnosed 
with PA and then transferred to the Urology Department for AVS. AVS and CT are used 
to establish a lateralisation diagnosis. Antihypertensives including angiotensin 
converting enzyme inhibitors (ACEI), angiotensin receptor blocker (ARB), beta-
receptor blocker, and dihydropyridine calcium antagonist must be stopped two weeks 
before AVS. Aldosterone receptor antagonist must be stopped at least four weeks before 
AVS. We choose an α-receptor blocker to replace the interfering medications and to 
maintain blood pressure at its pre-medication-replacement level. The clinic features of 
all enrolled subjects, including blood pressure, blood biochemical tests, and drug 
dependence, were recorded before and after surgery. Laparoscopic total adrenalectomy 
was performed when a dominant gland was detected by AVS.  
 
Blood biochemical tests 
The plasma renin activity (PRA) was measured by radioimmunoassay using a 
commercial kit (Northern Institute of Biotechnology, Beijing, China). The plasma 
aldosterone concentration (PAC) was measured by radioimmunoassay using a 
commercial kit (Jiuding Biological Technology Ltd., Tian Jin, China). 
 
Adrenal vein sampling interpretation 
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All AVS procedures were performed by an experienced interventional radiologist in a 
sequential fashion without cosyntropin stimulus. Before AVS was performed, the 
operator needs to identify the position of the adrenal gland and adrenal vein (AV) from 
the contrast-enhanced CT. A 3–4 ml blood sample was obtained at each of the following 
four sites: inferior vena cava (IVC) below the confluence of the renal veins, IVC above 
the confluence of the renal veins, left adrenal vein (LAV), and right adrenal vein (RAV). 
When taking blood samples from the RAV, the radiologist should firstly find a point of 
attachment for the catheter and then gently inject 3–5 ml of iodine contrast medium into 
the catheter to confirm its position. If the appearance of contrast agent is observed in 
the adrenal gland under X-ray, it confirms that the blood from the adrenal vein drains 
into the catheter.  
When adrenal vein/inferior vena cava (IVC) cortisol ratios (selective index — SI) are 
≥ 3:1, we considered this procedure as a successful cannulation. Lateralisation index 
(LI) was calculated by dividing the aldosterone to cortisol ratio of the dominant adrenal 
gland by that of the non-dominant gland. Unilateral disease is diagnosed if LI ≥ 2 on 
the premise of successful cannulation. Patients with SI < 3, which is considered as failed 
cannulation, were diagnosed using aldosterone index (AI) to determine the dominant 
gland. AI is calculated by dividing the adrenal vein aldosterone concentration by the 
aldosterone concentration of IVC. If the AI of one side is < 1 and > 1 on the contralateral 
side, we diagnosed the contralateral adrenal gland as the dominant gland. Otherwise, 
the patients were advised to accept drug therapy. 
 
Statistical analysis 
The statistical analysis was performed by an in-house script based on R software 
(https://www.r-project.org). The Kolmogorov-Smirnov test was used if the data showed 
a normal distribution. Also, if the data were normally distributed, Student’s t-test was 
used to compare the difference of demographic data between different subgroups. Two-
way repeated-measures ANOVA and Tukey’s post hoc test were applied for the 
detection of significant differences between groups at different follow-up points. 
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Accordingly, these values were presented as mean ± standard error (SD). When data 
were not normally distributed, the Wilcoxon signed-rank test was performed, and the 
values were listed as medians (upper-lower quartile). The drug dependence was tested 
with chi-square (χ2) test, which was corrected by Fisher’s exact test. Receiver operator 
characteristic (ROC) curve analysis was performed to calculate the predictive power of 
the sensitivity and specificity of our developed strategy. A two-tailed p value less than 
0.05 was considered as significant, unless specifically indicated. 
 
Results  
Demography of enrolled patients 
The clinical characteristics of all included patients are illustrated in Table I. The 
proportion of males was 42.24% and females 57.76%. The age, body mass index (BMI), 
and blood pressure (systolic blood pressure/diastolic blood pressure) for all the patients 
was 44.95 ± 11.35 years, 24.21 ± 3.25 kg/m2, and 155.44 ± 20.62/98.59 ± 15.92 mmHg, 
respectively. For primary screening of PA in hypertensive patients, we measured the 
plasma potassium levels, PRA, angiotensin 2 concentrations, and PAC, as well as ARR, 
for individuals in lying and standing positions. The mean concentrations of these 
biochemical parameters in the lying position were 3.32 ± 0.63 mmol/L, 0.1 (0.04–0.21) 
ng/mL·h, 61.78 ± 13.75 ng/L, 32.11 (25.13–39.05) ng/dL, and 309.27 (139.24–765.08) 
(ng/dL)/(ng/mL·h), respectively. In the standing position, these values were 3.29 ± 0.6 
mmol/L, 0.32 (0.12–0.61) ng/mL·h, 60.3 (55.75–72.95) ng/L, 29.42 (23.81–35.55) 
ng/dL, and 91.53 (2.45–210.44) (ng/dL)/(ng/mL·h), respectively.  
 
 
 
The aldosterone in AVS/peripheral blood ratio could be used to determine the 
dominant gland 
As illustrated in Figure 1, all patients experienced decreased SBP, DBP, and aldosterone 
and increased renin activity after treatment, which implied a recovery of PA. As 
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mentioned above, we conducted a modified method to identify the dominant gland. 
Patients with dominant adrenal gland based on successful AVS were included in 
subgroup 2 (n = 75), while the patients who would undergo the operation based on the 
existence of a suppressed side after a failed sampling in the right side were enrolled in 
subgroup 1 (n = 41). The clinical features of the two groups are listed in supplemental 
Table I and supplemental Table 2, separately. The clinical outcomes of patients in 
subgroup 1 and 2 were compared and are exhibited in Figure 1. The systolic and 
diastolic blood pressures were not significantly different before surgery in these two 
subgroups (Table IIA and Table IIB, p-value > 0.05). The most influential indicators of 
PRA, ARR, and PAC were similar in subgroup 1 and 2 before surgery (Fig. 1, p-value > 
0.05), which indicated that the baseline conditions in these two groups were similar 
before surgery. In addition, there were no significant differences of blood pressure 
between subgroup 1 and 2 in the follow-up periods (p-value for sixth month > 0.05, p-
value for the 12th month > 0.05). The plasma angiotensin and aldosterone in subgroup 
1 and 2 were not statistically significant for the sixth month (p-value for the sixth month > 
0.05) and were within normal range after 12 months. In brief, aldosterone, angiotensin, 
and blood pressure showed no obvious differences between the two subgroups after 
operation and were within the normal range after 12 months. Exhibiting similar clinical 
results from our developed method to those recommended in guidelines, it can be 
concluded that the aldosterone concentration measured in AVS and peripheral blood 
was useful to determine the dominant gland in patients with failed sampling in the right 
side. Moreover, the drug dependence in patients in subgroup 1 decreased significantly 
before and after surgery (Tab. II, p-value < 0.05). The patients who took at least one 
class of drug decreased from 40 to 10 after surgery. The drug dependence in patients in 
subgroup 2 decreased remarkably before and after surgery (Tab. III, p-value < 0.05). 
The patients who take at least one class of drug decreased from 75 to 13 after surgery. 
As illustrated in Figure 2, AUC = 0.76, sensitivity — 91.3%, specificity — 67.53%, 
likelihood ratio — 2.81, ROC analysis was performed to test the specificity and 
sensitivity based on AI in subgroup 2. The AUC for dominant gland detection was 0.76, 
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which resulted in 91.3% sensitivity and 67.53% specificity. The positive and negative 
likelihood ratios were 2.81. 
 
Patients’ age and gender showed close correlation to clinical outcome 
For patients with failed sampling in the right side and using AI to determine the 
dominant gland, we wondered if the factors of age, gender, and tumour location could 
affect the clinical outcomes of these patients. The patients were sub-classified 
according to age (< 60 or > 60 years old; listed in Fig. 3), gender (male or female; listed 
in Fig. 4), and tumour location (left or right; listed in supplemental Fig. 1).  
Interestingly, the SBP for patients elder than 60 years was higher than for those younger 
than 60 years after six months and 12 months (Fig. 3, p in sixth month < 0.05, p in 12th 
month < 0.05). DBP showed an identical variation trend as SBP (Fig. 3, p in 12th month 
< 0.05). In addition, the SBP for male patients was also higher than female patients after 
six months and 12 months (Fig. 4, p in sixth month < 0.05, p in 12th month < 0.05). No 
significant differences of these indicators between left and right tumour were detected 
(supplemental Fig. 1, all p > 0.05). These data suggested that the strategy for 
determination of dominant gland in our routine might be affected by age and gender.  
 
Discussion  
In this retrospective study, we developed a modified strategy for detecting the dominant 
gland in primary aldosteronism, and compared their clinical results with patients who 
underwent a successful cannulation in the right adrenal vein. For modified strategy in 
subtyping PA, the aldosterone levels in the adrenal vein and IVC were employed for 
the determination of the dominant gland in patients when sampling in the right side had 
failed. No significant differences in clinical outcome between this way and successful 
AVS were identified.  
 Primary aldosteronism is one of the most common causes of endocrine 
hypertension [12]. The pathogenesis of PA is still unclear at present. Generally, patients 
with PA exhibited a state of high plasma aldosterone levels and low plasma renin 
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concentrations, which were caused by continuously excessive autonomous synthesis 
and release of aldosterone. Multiple pathologies of PA have been reported. About two-
thirds of PA patients were attributed to bilateral adrenal hyperplasia, while aldosterone-
producing adenomas accounted for about one-third of the patients with excessive 
aldosterone and insufficient renin activity [13]. The overgeneration of aldosterone in 
PA was reported to show various detrimental effects, such as cardiovascular events 
including cerebrovascular accidents and myocardial infarctions, uncontrolled blood 
pressure, disorders of function and metabolism, etc. [14–20]. 
Due to the widespread prevalence in hypertensive patients [21] and poor outcomes of 
these patients [22], it is of great importance for early screening and diagnosis of PA. 
Currently, the recommended tests for screening the PA include measurement of plasma 
PRA, PAC, and ARR [23]. In this study, we screened the cases of high aldosterone and 
low renin activity in hypertensive patients. Captopril-challenge test or saline-loading 
test were also performed in this study, to establish the diagnosis of PA. The patients 
who met the diagnosed criteria of PA were sent for CT and AVS as routine management. 
The specificity and sensitivity of CT for PA subtyping was about 71% and 87%, 
respectively [24]. The CT scan is optimal for detection of anatomical lesions in the 
adrenal gland, but it fails to identify the functional abnormalities. A retrospective study 
showed that about 37.8% of the patients with CT diagnosis of PA subtype were 
inconsistent with the results from AVS [22]. Approximately 14.6% of cases with AVS-
identified bilateral aldosterone over-secretion showed unilateral lesions in CT scanning; 
about 19.1% of patients with AVS confirmed with unilateral aldosterone over-secretion 
were demonstrated to suffer bilateral lesions in CT scanning. More importantly, about 
3.9% of the patients resected the adrenal gland in the incorrect side, was identified by 
AVS with a contralateral aldosterone excessive secretion. Although a recent study 
revealed no significant difference of PA diagnosis and clinical benefits between CT and 
AVS, the AVS was generally considered as the gold standard for PA subtyping. We 
combined CT and AVS in this study for PA subtyping.  
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Adrenal vein sampling is not easy to achieve, due to the technique and varied 
anatomical structure of the adrenal vein, especially when obtaining a blood sample from 
the right side. The anatomy for confluence of the right adrenal vein and inferior vena 
cava (IVC) is complex. In addition, the angle of these two veins is inconvenient for 
intubation, which always leads to failure of sampling. For patients with failed sampling 
in the right side there are no consistent recommendations for determination of the 
dominant gland. In practical use, right adrenal venous sampling often contains a 
mixture of adrenal venous blood and peripheral blood because the blood sample from 
the right adrenal vein is usually obtained at the peristome of the confluence where the 
right adrenal vein is collected into the IVC. In some cases, the RAV forms a common 
trunk with an accessory right hepatic vein before it drains into the IVC, which makes it 
almost impossible to obtain an RAV blood sample without the mixture of blood from 
the right hepatic vein. As a result, the SI value could be lower than 3 and the sampling 
could be defined as a failure, which might mislead the subsequent therapeutic choice. 
In this study, we, for the first time, used the aldosterone concentrations to directly 
determine the dominant gland. The pathophysiological basis for this strategy is that the 
aldosterone concentration in the right adrenal venous blood or even in mixture of 
adrenal venous blood and peripheral blood should be higher than that in the peripheral 
blood in normal conditions. Only when the high concentration of aldosterone in one 
side, caused by high autonomous aldosterone secretion from APA, inhibits the activity 
of renin angiotensin aldosterone system (RAAS), will the aldosterone secretion of the 
contralateral adrenal gland be suppressed; as a result, the aldosterone concentration of 
the contralateral side could be lower than that in the peripheral blood. According to the 
clinical outcomes in these patients, determination of the dominant gland by this strategy 
is effective in clinical practice. A larger clinical study containing a larger sample size is 
now being conducted by our group to verify these findings. 
Our results suppled and consummated original guideline, which merited further 
researches. 
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Table I. Clinical features for all enrolled subjects 
Sex Male 49 (42.24%) 
 Female 67 (57.76%) 
    
BMI [kg/m2]  24.21  3.25  
    
Mean age [years] 44.95  11.35  
    
Blood pressure [mmHg]   
 Systolic 155.44  20.62  
 Diastolic 98.59  15.92  
Lying position   
Plasma renin activity   
    
Number of patients  114  
Activity [ng/mL*h] 0.1 0.04–0.21 
Plasma potassium   
    
Number of patients 114  
14 
 
Concentration [mmol/L] 3.32 0.63 
Plasma aldosterone  
    
Number of patients 114  
Concentration [ng/dL] 32.11 25.13–39.05 
Plasma angiotensin 2   
    
Number of patients 114  
Concentration [ng/L] 61.78 13.75 
ARR    
    
Number of patients 97  
Value [ng/dL]/[n
g/mL*h] 
309.27 139.24–765.08 
Standing position   
Plasma renin activity   
    
Number of patients  113  
Activity [ng/mL*h] 0.32 0.12–0.61 
Plasma potassium   
    
Number of patients 114  
Concentration [mmol/L] 3.29 0.6 
Plasma aldosterone  
    
Number of patients 113  
Concentration [ng/dL] 29.42 23.81–35.55 
Plasma angiotensin 2   
    
15 
 
Number of patients 113  
Concentration [ng/L] 60.3 55.75–72.95 
ARR    
    
Number of patients 113  
Value [ng/dL]/[ng/
mL*h] 
91.53 42.45–210.44 
 
All variables refer to baseline data unless otherwise stated. All quantitative and normally distributed 
variables are reported as mean ± standard deviation; non-normally distributed variables are presented as 
median with lower and upper quartiles in parentheses. P-values < 0.05 were considered statistically 
significant. 
 
Table IIA. Comparison of outcomes between subgroups 1 and 2 
 
    
Pre-operation 
   
Post-operation 
 
  
Subgroup 1 
(n = 41) 
 
Subgroup 2 
(n = 75) 
 
p 
value 
 
Subgroup 1 
(n = 41) 
 
Subgroup 2 
(n = 75) 
 
p 
value 
 
Systolic blood pressure 
[mmHg] 157.93 (18.39) 154.08 (21.74) 0.32 144.84 (16.35) 137.47 (15.93) 0.03 
Diastolic blood pressure 
[mmHg] 96 (87–106) 
 
104 (90.5–
110.5) 0.17 
88.5 (81–
96.75) 91 (80.5–100) 0.68 
Plasma renin activity 
0.32 (0.12–
0.61) 0.33 (0.13–0.61) 0.63 
0.39 (0.26–
0.67) 
0.64 (0.43–
0.77) 0.1 
Plasma aldosterone 
26.33 (19.95–
32.44) 
30.07 (26.28–
38.65) 0.02 12.45 (3.86) 
 
14.58 (5.31) 
 
0.07 
Plasma angiotensin 2 
61.63 (58.01–
70.86) 
59.55 (55.23–
73.84) 0.49 65.3 (12.44) 
 
63.41 
(10.38) 
 
0.54 
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ARR 
90.3 (39.57–
255.6) 
92.75 (43.33-
178.45) 0.99 
29.23 (17.13-
42.69) 
23.73 (15.04–
32.67) 0.37 
Plasma potassium 3.32 (0.51) 
 
3.28 (0.64) 
 
0.7 
4.36 (3.96-
4.71) 
3.96 (3.76–
4.16) 0.01 
 
Table IIB. Comparison of outcomes between subgroups 1 and 2 
    
6 months 
   
12 months 
 
  
Subgroup 1 
 
Subgroup 2 
 
p 
value 
Subgroup
1 
 
Subgroup 
2 
 
p 
value 
Systolic blood 
pressure 
[mmHg] 136.5 (125–147.75) 129 (122–135) 0.94 128 (120–133) 126 (120.5–134) 0.97 
Diastolic blood 
pressure 
[mmHg] 91 (80.5–100) 88 (84–92) 
 
0.64 86 (81–91) 
 
88.08(8.65) 
 
0.78 
Plasma renin 
activity 0.64 (0.43–0.77) 1.98 (1.44–2.31) 0.00 1.89 (1.54–2.38) 2.15 (1.76–3.79) 0.03 
Plasma 
aldosterone 
14.32 (10.55–
16.98) 
14.57 (12.67–
16.79) 0.69 
14.58 (13.21–
19.87) 
14.26 
(4.73) 
 
0.02 
Plasma 
angiotensin 2 
62.07 (56.39–
70.43) 
66.43 (58.54–
71.65) 0.61 
68.96 (58.86–
74.87) 
67.43 (59.05–
77.06) 0.89 
ARR 
23.73 (15.04–
32.67) 7.45 (6.2–9.96) 0.00 
7.88 (5.99–
10.34) 6.6 (4.46) 
 
0.00 
Plasma 
potassium 3.96 (3.76–4.16) 4.17 (4.02–4.65) 0.29 4.03 (3.66–4.25) 3.91 (3.54–4.25) 0.4 
 
Table III. Comparison of drug dependence in patients in subgroup 1 before and after 
surgery 
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Classes of drugs Before surgery 1 month after surgery 6 months after surgery p-value 
0 1 31 31 0.00* 
1 22 9 9  
2 13 1 1  
3 5 0 0  
n = 41; *p < 0.05, calculated by χ2 test 
 
Table IV. Comparison of drug dependence in patients in subgroup 2 before and after 
surgery 
 
Classes of drugs Before surgery 1 month after surgery 6 months after surgery p-value 
0 0 62 58 0.00* 
1 35 11 15  
2 33 2 0  
3 7 0 2  
n = 75; *p < 0.05, calculated by χ2 test 
 
Table VA. Clinical features for all enrolled subjects who are younger than 60 years and 
older than 60 years 
   Pre–operation    Post–operation   
  < 60   > 60  p 
value 
< 60  > 60  p 
value 
Systolic blood pressure 
[mmHg] 
155.95 (20.39) 152 
(22.54) 
 0.53 140.19 (16.07) 138.6 
(18.83) 
 0.76 
Diastolic blood pressure 
[mmHg] 
99 (89–
110) 
 99 (83–
107) 
 0.3 91 (82–
100) 
 88 (80–
98.5) 
 0.54 
Plasma renin activity 0.33 (0.11–0.61) 0.32 (0.13–
0.50) 
0.72 0.64 (0.39–0.79) 0.24 
(0.240.36) 
0.005 
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Plasma potassium 3.35 
(0.59) 
 2.93 
(0.53) 
 0.01 4.17 
(0.57) 
 3.99 (0.47)  0.3 
Plasma aldosterone 29.63 (24.62–
35.53) 
24.52 
(20.08–
34.08) 
0.3 13.66 (10.32–
16.64) 
11.47 (8.42–
13.99) 
0.15 
Plasma angiotensin 2 60.67 (55.41–
73.33) 
60.12 
(58.60–
70.96) 
0.82 64.57 (11.332) 60.7 (9.28)  0.31 
ARR  90.3 (42.71–
210.08) 
97.63 
(40.82–
198.58) 
0.94 24.15 (14.71–
34.68) 
41.26 (30.41–
53.30) 
0.04 
 
Table VB. Clinical features for all enrolled subjects who are younger than 60 years and 
older than 60 years 
    6 Months     12 
Months 
  
  < 60  > 60  p 
value 
< 60  > 60  p 
value 
Systolic blood pressure 
[mmHg] 
128 (120–136) 133 (131.5–144) 0.008 124 
(120–
133) 
 133 (128–
143) 
 0.002 
Diastolic blood 
pressure [mmHg] 
88 (81–
93) 
 90 (88–102)  0.06 86 
(81–
91) 
 91 (89–
100.5) 
 0.02 
Plasma renin activity 2.34 (1.67–3.65) 2.4 (1.9–3.035) 0.61 2.01 (1.67–
2.83) 
2.45 (1.54–3.33) 0.58 
Plasma potassium 4.21 (4.02–4.76) 4.32 (4.21–4.86) 0.13      
Plasma aldosterone 14.52 (12.32–
18.31) 
13.74 (13.16–
15.44) 
0.73 13.76 (11.76–
16.43) 
14.2 (11.435–
19.45) 
0.72 
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Plasma Angiotensin 2 67.09 
(12.63) 
 62.63 
(10.23) 
 0.14 67.4297 
(10.8) 
69.84 (10.43)  0.42 
ARR  6.21 (4.38–8.41) 5.99 (5.26–6.74) 0.51 6.79 (4.48–
9.39) 
6.5 (5.22–7.82) 0.96 
 
Table VIA. Clinical features for all enrolled male subjects and female patients 
    Pre-
operation 
   Post-operation  
  Male  Female  p 
value 
Male  Female  p 
value 
Systolic blood pressure 
[mmHg] 
157.22 (20.64) 154.13 
(20.66) 
0.43 139.13 (18.08) 127.6 
(11.17) 
 0.65 
Diastolic blood pressure 
[mmHg] 
105 (90–
112) 
 98 (87.5–
107) 
 0.09 95 
(82–
101) 
 80 (87–96)  0.06 
Plasma renin activity 0.35 (0.16–0.60) 0.32 (0.1–
0.59) 
0.27 0.51 (0.34–
0.75) 
0.64 (0.32–0.76) 0.43 
Plasma potassium 3.31 
(0.68) 
 3.275 
(0.53) 
 0.74 4.07 (3.76–
4.47) 
4 (3.77–
4.66) 
 0.65 
Plasma aldosterone 27.99 (22.89–
35.01) 
29.86 (24.66–
35.72) 
0.51 15.42 (10.99–
18.25) 
11.86 (9.48–
14.95) 
0.03 
Plasma angiotensin 2 63.21 (55.91–
73.09) 
59.75 
(55.505–
72.02) 
0.65 63.03 
(8.511412) 
64.86 
(12.73) 
 0.49 
ARR  65.63 (40.06–
170.69) 
100.43 
(55.02–
247.42) 
0.17 29.23 (17.96–
45.35) 
23.57 (13.73–
33.86) 
0.09 
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Table VIB. Clinical features for all enrolled male subjects and female patients 
    6 months    12 months  
  Male  Female  p 
value 
Male  Female  p 
value 
Systolic blood pressure 
[mmHg] 
133 (126–
141) 
125 (118.3–133) 0.01 131 
(123–
142) 
 124 (120–
131.5) 
0.003 
            
Diastolic blood pressure 
[mmHg] 
89 
(84–
97) 
 88 (81–90)  0.06 89 (83–
94) 
 95 (80–
91) 
 0.03 
            
Plasma renin activity 2.41 (1.77–
3.87) 
2.22 (1.71–3.12) 0.57 2.13 (1.67–3.81) 2.01 (1.66–
2.60) 
0.43 
            
Plasma potassium 4.52 (4.12–
4.87) 
4.21 (4.03–4.64) 0.04      
            
Plasma aldosterone 13.52 (11.42–
16.43) 
14.66 (13.12–
18.84) 
0.01 13.42 (11.67–
14.98) 
14.22 (11.71–
20.315) 
0.19 
            
Plasma angiotensin 2 65.6 
(11.35635) 
67.17 
(13.15) 
 0.49 67.65 
(10.49) 
 67.81 
(11) 
 0.93 
            
ARR  5.12 
(4–
7.22) 
 6.67 (5.33–8.77) 0.013 6.42 (4.14–7.91) 7 (5.07–
10.07) 
 0.07 
 
Table VIIA. Clinical outcome for subjects suffering diverse locations of tumour 
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    Pre–operation    Post–
operation 
 
  Left  Right  p 
value 
Left  Right  p 
value 
Systolic blood pressure 
[mmHg] 
152 (139.75–
167) 
162.5 (135.5–
172.25) 
0.81 140.4156 
(16.83382) 
139 
(15.51659) 
0.81 
Diastolic blood pressure 
[mmHg] 
99 (89–110.25) 99 (88.25–
107.25) 
0.53 91 (81–
101) 
 87 
(81–
98) 
 0.53 
Plasma renin activity 0.34 (0.13–
0.645) 
0.2 (0.1–
0.4325) 
0.1 0.61 (0.31–0.86) 0.55 (0.39–
0.6925) 
0.1 
Plasma potassium 3.26 
(0.53) 
 3.36 
(0.73) 
 0.46 4.03 (3.76–4.29) 4.21 (3.84–
4.83) 
0.46 
Plasma aldosterone 28.47 (23.71–
36.64) 
29.73 (23.95–
34.03) 
0.95 14 (11.4–16.58) 10.56 (8.21–
15.6225) 
0.95 
Plasma angiotensin 2 60.3 (57.1–
73.65) 
60.21 (55.17–
71.06) 
0.39 63.28 (56.275–
70.6875) 
62.21 
(55.73–
70.975) 
0.39 
ARR  83.45 (40.06–
178.45) 
138.94 (53.4–
241.45) 
0.18 25.87 (15.6–
39.12) 
23.01 
(14.49–
40.53) 
0.18 
 
Table VIIB. Clinical outcome for subjects suffering diverse locations of tumour 
 
    6 
Mon 
    12 
Mon 
  
  Left  Right  p 
value 
Left  Right  p 
value 
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Systolic blood pressure 
[mmHg] 
130.29 
(12.47) 
129.4167 
(11.29) 
0.71 128 (121.75–
134.25) 
124.5 (120–
133.25) 
0.71 
Diastolic blood pressure 
[mmHg] 
88 (81–92.25) 88 (83–97.25) 0.70 88 
(81–
92) 
 84 (81–92.25) 0.70 
Plasma renin activity 2.27 (1.67–
3.16) 
2.49 (1.93–
3.90) 
0.22 2 
(1.56–
2.7) 
 2.25 (1.78–
3.35) 
0.22 
Plasma potassium 4.21 (4.02–
4.73) 
4.27 (4.11–
4.76) 
0.36      
Plasma aldosterone 14.25 (12.64–
17.465) 
14.26 (11.56–
18.46) 
0.87 13.69 (11.64–
16.18) 
14.24 (11.75–
18.65) 
0.87 
Plasma Angiotensin 2 66.48 (12.20) 66.56 (12.99) 0.98 68.44 
(10.46048) 
66.2 
(11.34573) 
0.98 
ARR  6.74 (4.79–
8.55) 
5.12 (3.94–
6.71) 
0.03 6.96 (4.79–
8.99) 
5.75 (4.44–
7.79) 
0.03 
 
Figure 1. Receiver operator characteristic (ROC) curve analysis results 
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Supplement 
Table 1. Clinical characters for patients in subgroup 1 
Sex Men 12 (29.27%) 
 Women 29 (70.73%) 
    
BMI [kg/m2]  23.68  3.12 
    
Mean age [years] 46.49  11.57 
    
Blood pressure [mmHg]   
 Systolic 157.93  18.39 
 Diastolic 97.41  12.12 
    
Lying position   
Plasma renin activity   
Number of patients  41  
Activity [ng/mL*h] 0.85 1.65 
    
Plasma potassium   
Number of patients 41  
Concentration [mmol/L] 0.32 0.12–0.61 
    
Plasma aldosterone  
Number of patients 41  
Concentration [ng/dL] 26.33 19.95–32.44 
    
Plasma angiotensin 2   
Number of patients 41  
Concentration [ng/L] 61.63 58.01–70.86 
    
ARR    
Number of patients 41  
Value [ng/dL]/[ng/
mL*h] 
90.3 39.5–255.60 
    
Standing position   
Plasma renin activity   
Number of patients  41  
Activity [ng/mL*h] 0.1 0.04–0.24 
    
Plasma potassium   
Number of patients 41  
Concentration [mmol/L] 3.42 0.63 
    
Plasma aldosterone  
Number of patients 41  
Concentration [ng/dL] 28.77 23.13–36.73 
    
Plasma angiotensin 2   
Number of patients 41  
Concentration [ng/L] 62.94 50.94–73.37 
    
ARR    
Number of patients 41  
Value [ng/dL]/[ng/
mL*h] 
260 104.83–711.38 
 
Table 2. Clinical features for patients in subgroup 2 
Sex Men 37 (49.33%) 
 Women 38 (50.67%) 
    
BMI [kg/m2]  24.50  3.31  
    
Mean age [years] 44.11  11.22  
    
Blood pressure [mm Hg]   
 Systolic 154.08  21.74  
 Diastolic 99.24  17.70  
    
Lying position   
Plasma renin activity   
Number of patients  75  
Activity [ng/mL*h] 0.33 0.13–0.61 
    
Plasma potassium   
Number of patients 75  
Concentration [mmol/L] 3.28 0.64 
    
Plasma aldosterone  
Number of patients 75  
Concentration [ng/dL] 30.07 26.28–38.65 
    
Plasma angiotensin 2   
Number of patients 75  
Concentration [ng/L] 64.57616438 15.44681913 
    
ARR    
Number of patients 75  
Value [ng/dL]/[ng/
mL*h] 
92.75 43.33–
178.45 
    
Standing position   
Plasma renin activity   
Number of patients  75  
Activity [ng/mL*h] 0.1 0.05–0.18 
    
Plasma potassium   
Number of patients 75  
Concentration [mmol/L] 3.27 0.63 
    
Plasma aldosterone  
Number of patients 75  
Concentration [ng/dL] 33.365 25.595–
44.32 
    
Plasma angiotensin 2   
Number of patients 75  
Concentration [ng/L] 58.575 51.33–
67.1675 
    
ARR    
Number of patients 75  
Value [ng/dL]/[ng/
mL*h] 
329.1 159.83–
892.33 
 
 
